Month: August 2020

                                                                  Information mensuelle relative au nombre total de droits de voteet d’actions composant le capital socialAu 31 juillet 2020Article 223-16 du Règlement Général de l’Autorité des Marchés FinanciersPlaces de cotation :– Bourse de Casablanca : Marché principal / MA 0000011488– Euronext Paris : Eurolist (valeurs étrangères) / MA 0000011488– LEI : 254900LH0G1ZIZ78Y462–    Présence dans les statuts de Maroc Telecom d’une clause imposant l’obligation de déclaration de franchissement de seuil complémentaire de celle relative aux seuils légaux : OUIAvenue Annakhil, Hay Riad Rabat MAROCTel + 212 (0) 537 71 21 21 / fax + 212 537 71 48 60Itissalat Al Maghrib – Maroc Telecom : Société anonyme à Directoire et à Conseil de surveillance au capital de 5.274.572.040...

CAISSE REGIONALE DE CREDIT AGRICOLE MUTUEL SUD RHONE ALPES SOCIETE COOPERATIVE à CAPITAL VARIABLEAu capital actuel de 69 850 962,75 euros

Phase 1 study will evaluate safety and immunogenicity in Chinese participants to support potential regulatory approval pathway in ChinaTotal of 144 participants to be enrolled in two age groups (18-55 and >55 years)Trial participants to receive either 10µg or 30µg of BNT162 or a placeboClinical supply from BioNTech’s GMP-certified mRNA production facilities in EuropeMAINZ, Germany, and SHANGHAI, China, Aug. 05, 2020 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma” or “Group”; Stock Symbol: 600196.SH, 02196.HK), today announced that the first 72 participants have already been dosed with BNT162b1 following IND approval by the Chinese regulatory authority, National Medical Products Administration (NMPA). BioNTech and Fosun Pharma are jointly...

Phase-1-Studie wird Sicherheit und Immunogenität in chinesischen Probanden evaluieren, um eine potenzielle Zulassung in China zu unterstützenInsgesamt werden 144 Probanden in zwei Altersgruppen in die Studie eingeschlossen (18-55 und >55 Jahre)Probanden erhalten entweder 10 µg oder 30 µg BNT162 oder PlaceboMaterial für klinische Studie wird von BioNTechs GMP-zertifizierten mRNA-Produktionsstätten in Europa bereitgestellt             MAINZ, Deutschland, und SHANGHAI, China, Aug. 05, 2020 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) und Shanghai Fosun Pharmaceutical (Group) Co., Ltd („Fosun Pharma“ oder „die Gruppe“; Börsensymbol: 600196.SH, 02196.HK) gaben heute bekannt, dass die ersten 72 Probanden mit BNT162b1 geimpft wurden, nachdem die chinesische Behörde National Medical Products Administration...

5 August 2020Announcement no. 33/2020Alm. Brand A/S – Annual General Meeting 28 August 2020With reference to the information obligations for issuers of listed securities on Nasdaq Copenhagen A/S we attach the notice and the agenda of the annual general meeting and the complete proposals for the annual general meeting to be held on 28 August 2020.ContactPlease direct any questions regarding this announcement to:Senior Vice President, Investor RelationsLars HolmMobile no. +45 2510 4717Senior Investor Relations Officer                                                                               Mikael Bo Larsen                                                                                                             Mobile no. +45 5143 8002      AttachmentsAS 33 2020 – Notice of annual general meetingNotice of annual general meetingAgenda...

5. august 2020Selskabsmeddelelse nr. 33/2020Alm. Brand A/S – Ordinær generalforsamling den 28. august 2020Med henvisning til oplysningsforpligtelserne for udstedere af børsnoterede værdipapirer på Nasdaq Copenhagen A/S fremsendes vedhæftet indkaldelse samt dagsorden og de fuldstændige forslag til den ordinære generalforsamling i Alm. Brand A/S den 28. august 2020.        KontaktEventuelle henvendelser vedrørende denne selskabsmeddelelse bedes rettet til:Direktør for Investor RelationsLars Holmmobil nr. 25 10 47 17Senior Investor Relations Officer                                                                               Mikael Bo Larsen                                                                                                             mobil nr. 51 43 80 02               Vedhæftede filerAS 33 2020 – Indkaldelse til generalforsamlingAktionærbrevDagsorden...

On Wednesday, 12 August 2020, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its six-month interim report (Q2) 2020.ALK will host a meeting for analysts and institutional investors that day at 1.30 p.m. (CEST) at which Management will review the financial results, the outlook and answer questions.The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins.Participants in the conference call are kindly requested to call in before 1.25 p.m. (CEST). Danish participants should call in on tel. +45 3544 5577 and international participants should call in on tel. +44 333 300 0804 or +1 631 913 1422. Please use the Participant Pin Code: 73006317#.ALK-Abelló A/SFor further information please contact:Investor Relations: Per Plotnikof, tel. +45 4574...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for første halvår (Q2) 2020 onsdag den 12. august 2020.ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for investorer og analytikere, hvor ledelsen fremlægger resultater og forventninger samt besvarer spørgsmål.Mødet audiocastes på https://ir.alk.net, hvor den tilhørende præsentation vil være tilgængelig kort før start.Deltagere i telefonkonferencen bedes ringe ind senest kl. 13.25 (CEST). Danske deltagere skal ringe på tlf. 3544 5577, mens internationale deltagere skal ringe på +44 333 300 0804 eller+1 631 913 1422. Benyt venligst følgende deltager-pinkode: 73006317#ALK-Abelló A/SFor yderligere oplysninger kontakt venligst:Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525Presse: Jeppe Ilkjær, mobil 3050 2014Om ALKALK er en global, specialiseret...

 AttachmentEN_PGE confirmation PR August 5 F